Lilly Acquires Orna Therapeutics to Advance Cell Therapy for Autoimmune Diseases
Summary
Lilly has announced its acquisition of Orna Therapeutics, a biotechnology startup specializing in circular RNA medicines. The deal, valued at up to $2.4 billion, will allow Lilly to utilize Orna’s technology to develop cell therapies for autoimmune conditions. This acquisition is part of Lilly’s strategy to expand its pipeline of gene therapies and gene editing treatments.
Access impact
This acquisition has pricing and reimbursement implications as Lilly aims to develop cell therapies for autoimmune diseases using Orna’s technology. The company’s interest in Orna’s lead project, which targets B cells in inflammatory diseases, could lead to potential pricing strategies and reimbursement considerations for these therapies in the future. Additionally, this deal is part of Lilly’s larger strategy to expand its portfolio in the genetic medicine space, which could impact drug pricing and market access for these treatments.
Top-3 domain lens
Clinical Effectiveness
Orna’s lead project, ORN-252, has shown promising results in preclinical studies for targeting B cells in inflammatory diseases. This could have a significant impact on the clinical effectiveness of cell therapies for autoimmune conditions.
Cost-Effectiveness
Lilly’s acquisition of Orna could have cost implications for the development and commercialization of cell therapies for autoimmune diseases. This could potentially impact the cost-effectiveness of these treatments for patients and payers.
Comparator Appropriateness
This deal highlights the growing interest in in vivo cell therapies, which could potentially become a more convenient and cost-effective alternative to ex vivo approaches. This could impact the appropriateness of comparator treatments for autoimmune diseases.
Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug
CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list
Source
source: https://www.biopharmadive.com/news/lilly-orna-acquire-in-vivo-cell-therapy-autoimmune/811692/